Trials / Terminated
TerminatedNCT05835011
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
A Phase 2 Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab for Previously Untreated Subjects With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Astex Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to evaluate the preliminary safety and efficacy of oral decitabine/cedazuridine in combination with magrolimab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine/Cedazuridine | Oral FDC tablets administration |
| DRUG | Magrolimab | IV administration |
Timeline
- Start date
- 2023-06-27
- Primary completion
- 2023-08-21
- Completion
- 2023-08-21
- First posted
- 2023-04-28
- Last updated
- 2024-10-02
- Results posted
- 2024-10-02
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05835011. Inclusion in this directory is not an endorsement.